BIIB - Biogen says new Leqembi formulation better than IV version
2023-10-25 17:51:31 ET
More on Biogen
- Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges
- Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)
- Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
- Biogen updates Phase 1 data for Ionis-partnered Alzheimer’s drug
- FDA approves Biogen’s biosimilar to Roche's arthritis drug Actemra
For further details see:
Biogen says new Leqembi formulation better than IV version